Adjuvant combination chemotherapy or mono-chemotherapy with radiation significantly prolonged mean survival in primary cardiac sarcoma patients to 45.7 months compared to 4.2 months with other or no adjuvant therapies.
Observational (n=113)
No
Surgical excision of primary cardiac tumors yields excellent long-term survival for benign masses, while malignant tumors have a poor prognosis but survival can be significantly prolonged with adjuvant multimodality therapy.
Absolute Event Rate: 45.7% vs 4.2%
p-value: p=<0.05
BACKGROUND: Primary tumors of the heart represent an exceedingly rare entity in cardiac surgery and literature regarding management and outcome is rare. The aim of this study was to translate 15 years of experience in both multimodal diagnosis and surgical treatment of one of the largest collective of patients in literature into a detailed analysis of patient prognosis, mean survival and best treatment approach. METHODS AND RESULTS: All patients who underwent open-heart surgery at the Hospital of the Medical University of Vienna for primary cardiac tumor excision between 1999 and 2014 were analyzed retrospectively. Mean follow-up was 76.8 months. Descriptive statistical measurements were applied. 113 patients were identified, 71 (62.8%) female and 42 (37.2%) male patients with a mean age of 57.9 ± 16.8 years. 90.3% (n = 102) masses were benign, 9.7% (n = 11) were malignant. Complete resection was possible for 99% and for 18.2% of benign and malignant masses, respectively. 2.9% of benign tumors and 45.5% of malignant tumors relapsed. The 30-day mortality was 1.8% (n = 2). Mean survival was 187.2 ± 2.7 months and 26.2 ± 9.8 months for benign and malignant pathologies, respectively. Sarcoma patients who underwent adjuvant combination-chemotherapy or adjuvant mono-chemotherapy and radiation had a statistically significant survival advantage of 41.5 months. CONCLUSION: Primary cardiac tumors remain challenging in the clinical setting. A multimodality treatment approach especially for sarcoma patients prolongs mean survival and should be regarded as the standard of care.
Habertheuer et al. (Fri,) conducted a observational in Primary cardiac tumors (n=113). Adjuvant combination chemotherapy or mono-chemotherapy with radiation vs. Radiation alone, mono-chemotherapy alone, or no adjuvant therapy was evaluated on Mean survival (months) (p=<0.05). Adjuvant combination chemotherapy or mono-chemotherapy with radiation significantly prolonged mean survival in primary cardiac sarcoma patients to 45.7 months compared to 4.2 months with other or no adjuvant therapies.